Propafenone

Rythmol

Uncategorized

Standard

Half-life

2-10 hours (extensive metabolizers); 10-32 hours (poor metabolizers)

Protein Binding

85-97%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Proarrhythmic effects — increased mortality in post-MI patients

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Blocks sodium channels, has weak beta-blocking and calcium channel blocking properties

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Persistent Atrial Fibrillation
·Atrial Fibrillation (AF)
·Diseases of the Circulatory System
·Atrial Flutter
·Mild Cognitive Impairment

Interactions

No curated interaction pairs are recorded for Propafenone. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Dizziness
Metallic taste
Nausea
Constipation

Food, alcohol & herbal

Food

Food increases bioavailability

Alcohol · moderate

Additive cardiac depression

Pharmacokinetics

Half-life: 2-10 hours (extensive metabolizers); 10-32 hours (poor metabolizers)
Protein binding: 85-97%
Metabolised by: CYP2D6, CYP3A4, CYP1A2
Inhibits: CYP2D6

Pregnancy & lactation

Not recorded for Propafenone. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Propafenone

Rythmol

Uncategorized

Standard

Half-life

2-10 hours (extensive metabolizers); 10-32 hours (poor metabolizers)

Protein Binding

85-97%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Proarrhythmic effects — increased mortality in post-MI patients

Clinical alerts

Boxed warning

1 boxed warning

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Blocks sodium channels, has weak beta-blocking and calcium channel blocking properties

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Persistent Atrial Fibrillation
·Atrial Fibrillation (AF)
·Diseases of the Circulatory System
·Atrial Flutter
·Mild Cognitive Impairment

Interactions

No curated interaction pairs are recorded for Propafenone. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Dizziness
Metallic taste
Nausea
Constipation

Food, alcohol & herbal

Food

Food increases bioavailability

Alcohol · moderate

Additive cardiac depression

Pharmacokinetics

Half-life: 2-10 hours (extensive metabolizers); 10-32 hours (poor metabolizers)
Protein binding: 85-97%
Metabolised by: CYP2D6, CYP3A4, CYP1A2
Inhibits: CYP2D6

Pregnancy & lactation

Not recorded for Propafenone. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Propafenone Drug Profile | PharmaGraphX